Questions Surround Merck’s Withdrawal Of Keytruda Filing For Lung Cancer In EU

 
• By Ian Schofield

The withdrawal of Merck’s Keytruda NSCLC application in Europe suggests the firm filed too early, and it will now need to wait for the results of the Phase III KEYNOTE-189 study before submitting the drug again to the EMA.

Merck has withdrawn its Keytruda NSCLC application in the EU

More from Product Reviews

More from Pink Sheet